Endometriosis and GLP-1 Medications in India: What Women Need to Know About Semaglutide and Tirzepatide

Endometriosis and GLP-1 Medications in India: What Women Need to Know About Semaglutide and Tirzepatide

Endometriosis — a condition where tissue similar to the uterine lining grows outside the uterus — affects an estimated 25–42 million Indian women, making India one of the countries with the highest absolute burden of this disease worldwide. Despite its prevalence, endometriosis in India is chronically underdiagnosed: the average diagnostic delay is 8–12 years, and many women are dismissed with "painful periods are normal."

If you have endometriosis and are considering or currently taking GLP-1 receptor agonists like semaglutide (Ozempic, Rybelsus, Wegovy) or tirzepatide (Mounjaro), this guide answers the key questions.

Consult your healthcare provider before starting any medication. This article is for informational purposes only and does not replace advice from your gynaecologist, endocrinologist, or reproductive specialist.

The Indian Context: Why Endometriosis and GLP-1 Often Intersect

Several biological features of endometriosis make it particularly relevant to GLP-1 therapy in the Indian population:

1. Endometriosis and Insulin Resistance

Research published in peer-reviewed journals has demonstrated a significant association between endometriosis and insulin resistance, hyperinsulinaemia, and impaired glucose metabolism. Key findings:

• Women with endometriosis have measurably higher fasting insulin levels compared to controls
• Insulin promotes endometriotic lesion growth by stimulating aromatase activity (an enzyme that produces oestrogen within endometriotic tissue)
• Reducing insulin resistance — the primary mechanism of GLP-1 medications — may therefore reduce the hormonal environment that promotes endometriotic lesion survival and growth

2. Endometriosis and Obesity

While endometriosis is often associated with lean body phenotype in Western populations, Indian data tells a different story:

• A significant proportion of Indian women with endometriosis are overweight or obese, particularly those with concurrent PCOS (PCOS-endometriosis co-occurrence is documented in 6–8% of women with either condition)
• Visceral adiposity (abdominal fat) independently elevates oestrogen and inflammatory cytokines — both of which drive endometriosis progression
• Weight loss through GLP-1 therapy reduces visceral fat and systemic inflammation — both of which are mechanistically linked to endometriosis severity

3. Endometriosis and Inflammation

GLP-1 receptors are present in immune cells and have significant anti-inflammatory effects beyond their metabolic role. Endometriosis is fundamentally an inflammatory condition — the peritoneal fluid of women with endometriosis contains elevated levels of TNF-alpha, IL-6, IL-8, and prostaglandins. GLP-1's anti-inflammatory properties may therefore have a direct therapeutic relevance beyond weight loss.

What the Research Currently Shows

The direct evidence for GLP-1 therapy in endometriosis is emerging but not yet definitive. Here is an honest summary:

What is established:

• GLP-1 medications reduce insulin resistance and hyperinsulinaemia, which are documented drivers of endometriosis progression
• GLP-1 medications significantly reduce systemic inflammation (C-reactive protein, TNF-alpha, IL-6) — markers elevated in endometriosis
• Weight loss of 5–10% significantly reduces visceral adiposity and oestrogen production from fat tissue

What is emerging:

• Animal model studies have shown that GLP-1 receptor agonists directly reduce endometriotic lesion size and vascularity
• A 2023 case series from reproductive endocrinology clinics reported symptom improvement in some women with endometriosis on semaglutide — but this is anecdotal

What is not yet established:

• No large randomised controlled trial has been conducted on GLP-1 medications specifically for endometriosis treatment
• The degree of clinical symptom improvement (pain scores, lesion regression) attributable to GLP-1 beyond weight loss is not quantified
• GLP-1 medications should not be used as a substitute for established endometriosis treatments (surgery, hormonal therapy)

Interactions: GLP-1 and Common Endometriosis Treatments

If you are already on endometriosis therapy, understand how GLP-1 medications interact:

GLP-1 + Hormonal Treatments (Combined Oral Contraceptive Pill, Dienogest, GnRH Agonists)

Combined OCP (e.g., Yasmin, Diane-35, Lo-Ovral): GLP-1 medications slow gastric emptying, which may reduce the reliability of oral pill absorption. If you are taking an OCP for endometriosis suppression while on a GLP-1 medication:

• Use backup contraception (condom) for the first 3 months of GLP-1 therapy
• Discuss with your gynaecologist whether a progestin IUD (Mirena — available in India) or a progestin-only injection (Depo-Provera) might be more suitable — these are not affected by gut absorption changes

Dienogest (Visanne — available in India): Dienogest is an oral progestin used increasingly in India for endometriosis management. Like OCPs, it is orally absorbed and theoretically subject to the same gut absorption variability on GLP-1. However, the clinical significance is unclear. Discuss with your gynaecologist — the concern is more theoretical than proven.

GnRH Agonists (Zoladex/goserelin, Lupride/leuprolide — used for 6 months before IVF or surgery): These are given as subcutaneous injections — not affected by GLP-1's gut effects. No known interaction.

Progesterone IUD (Mirena): No interaction. This may actually be the most practical contraceptive/hormonal choice for women with endometriosis on GLP-1.

GLP-1 + NSAIDs for Pain (Ibuprofen, Diclofenac, Mefenamic Acid)

NSAIDs are commonly used for endometriosis-related dysmenorrhoea in India. GLP-1 slows gastric emptying — oral NSAIDs reach peak blood levels more slowly, which may reduce their pain-relief effectiveness at the usual time of administration. Practical advice:

• Take NSAIDs 30–60 minutes before expected peak pain onset (rather than when pain starts)
• Consider combining with a warm water bag for additional relief
• Diclofenac gel (topical) applied to the lower abdomen avoids gut absorption entirely

Step-by-Step Guidance for Indian Women With Endometriosis on GLP-1

Step 1: Tell Both Your Gynaecologist and GLP-1 Doctor

Many Indian women see their gynaecologist at a different clinic from their endocrinologist or GP who prescribes GLP-1. It is essential that:

• Your gynaecologist knows you are on GLP-1 (affects absorption of oral hormonal therapies)
• Your GLP-1 prescriber knows about your endometriosis and any concurrent hormonal or NSAID therapy
• Both coordinate on monitoring plans

Step 2: Track Your Symptoms — Pain Scores and Cycle Changes

When starting GLP-1 therapy, track your endometriosis symptoms using a simple diary:

• Daily pain score (0–10) for pelvic pain, dysmenorrhoea (period pain), dyspareunia (pain during sex), and defecatory pain
• Menstrual cycle length and flow
• Any changes in GI symptoms (distinguish endometriosis-related bowel symptoms from GLP-1 gut effects — both cause bloating, constipation, and diarrhoea)

Bring this diary to both your gynaecology and GLP-1 follow-up appointments. Women who track symptoms provide far better data for adjusting treatment.

Step 3: Understand That GLP-1 Is Not a Substitute for Endometriosis Treatment

GLP-1 medications are prescribed for obesity, type 2 diabetes, or cardiovascular risk reduction — not for endometriosis. Do not use GLP-1 as a replacement for:

• Hormonal suppression therapy (OCP, dienogest, GnRH agonists)
• Surgical management (laparoscopic excision — the gold standard)
• Fertility treatment if you are trying to conceive

GLP-1 may be a useful adjunct that improves the hormonal and inflammatory environment, but it does not treat endometriotic lesions directly.

Step 4: Anti-Inflammatory Diet — Aligned With GLP-1 Principles

For women with endometriosis, an anti-inflammatory dietary pattern has the most evidence for symptom modulation. This aligns well with the dietary recommendations for GLP-1 users:

Prioritise:

• Omega-3-rich fish (mackerel, sardines, tuna, salmon): 2–3 portions per week — anti-inflammatory effect documented in endometriosis
• Turmeric (haldi) + black pepper: Curcumin from turmeric has documented anti-inflammatory and anti-oestrogen effects in endometriosis models; black pepper increases curcumin absorption 20-fold
• Cruciferous vegetables (broccoli, cauliflower, phool gobi): Contain indole-3-carbinol, which promotes healthy oestrogen metabolism
• Flaxseeds (alsi): Lignans in flaxseeds modulate oestrogen signalling; 1 tbsp ground per day
• Dark leafy greens (palak, methi): High in magnesium, which reduces prostaglandin production and cramps

Reduce:

• Refined sugars and ultra-processed carbohydrates: Promote insulin resistance and inflammation
• Trans fats (vanaspati, commercially fried foods): Associated with increased endometriosis risk in prospective studies
• Excess red meat (particularly processed meats like sausages): Associated with higher endometriosis risk in large cohort studies

Step 5: Iron Monitoring

Women with endometriosis frequently experience heavy menstrual bleeding (menorrhagia), leading to chronic iron deficiency anaemia — already extremely prevalent in Indian women (NFHS-5 data: 57% of non-pregnant women are anaemic). GLP-1 medications further reduce iron absorption by suppressing appetite. Monitor:

• Full blood count every 6 months
• Serum ferritin (more sensitive than haemoglobin for iron deficiency)
• Supplement iron if ferritin is below 30 ng/mL — even in the absence of anaemia

Mistakes to Avoid

1. Assuming GLP-1 treats endometriosis: It does not. It may improve the metabolic and inflammatory environment, but endometriotic lesions require specific treatment.

2. Stopping hormonal endometriosis therapy because GLP-1 is "controlling things": Do not discontinue dienogest, OCP, or GnRH therapy without your gynaecologist's guidance.

3. Misattributing endometriosis pain to GLP-1 side effects (or vice versa): Both conditions cause abdominal bloating, cramping, and bowel symptoms. Tracking symptoms carefully helps distinguish them.

4. Neglecting surgical evaluation if needed: GLP-1 weight loss does not shrink endometriotic lesions. If you have severe endometriosis (Stage III/IV, deep infiltrating endometriosis, or endometrioma), surgical evaluation remains essential regardless of GLP-1 use.

5. Fertility planning without stopping GLP-1: If you have endometriosis and are planning IVF or natural conception, GLP-1 medications must be stopped before attempting conception. Coordinate timing with both your reproductive specialist and GLP-1 prescriber.

When to See a Doctor

Consult your doctor if you experience:

• New or significantly worsening pelvic pain after starting GLP-1
• Unusual bowel symptoms that do not follow the typical GLP-1 adjustment timeline (may be endometriosis-related bowel involvement)
• Breakthrough bleeding or significant menstrual changes beyond what is expected on GLP-1 therapy
• Planning to conceive — stop GLP-1 at the correct interval and coordinate care

Frequently Asked Questions

Q1: Can GLP-1 medications shrink endometriotic cysts (endometriomas)?

There is no established clinical evidence that GLP-1 medications shrink endometriomas. Animal studies show some lesion reduction, but human data is limited to case reports. Do not rely on GLP-1 to treat endometriomas — these require gynaecological management.

Q2: I have endometriosis and PCOS. Should I be on GLP-1?

The co-occurrence of PCOS and endometriosis is well-documented. GLP-1 addresses insulin resistance — a shared driver of both conditions. If you have both, GLP-1 therapy may be particularly beneficial for your metabolic health and may indirectly improve the hormonal milieu for both conditions. Discuss with your gynaecologist and endocrinologist together.

Q3: My periods have changed since starting GLP-1 — is this endometriosis worsening or a medication effect?

Both GLP-1 medications and endometriosis cause menstrual changes. GLP-1 typically causes changes due to weight loss and insulin sensitivity improvements (particularly beneficial for PCOS-related anovulation). If your pain scores have simultaneously worsened, consider endometriosis-related causes. If pain is unchanged or improved, the period changes are likely GLP-1 related. A pain and cycle diary will help clarify.

Q4: I am on Visanne (dienogest) for endometriosis and want to start Ozempic. Is this safe?

There is no known direct pharmacological interaction between dienogest and semaglutide. The theoretical concern is that GLP-1-slowed gastric emptying may affect dienogest absorption slightly. Clinically, this has not been reported as a significant problem. Discuss with your gynaecologist — she may advise taking dienogest at a fixed time relative to your Ozempic dose, or switching to a non-oral formulation.

---

This article is for informational purposes only. Consult your healthcare provider before starting any medication. Endometriosis is a complex condition requiring specialist gynaecological care — GLP-1 medications should only be used for their approved indications, not as primary endometriosis therapy.